Q1 2025 WAVE Life Sciences Ltd Earnings Call Transcript

May 8, 2025 / 12:30 PM GMT

Release Date Price: €5.8 (+0.87%)

Transcript 10-Q8-K

Key Points

Positve

WAVE Life Sciences Ltd (WVE) has made significant progress in its clinical pipeline, particularly in obesity, AATD, DMD, and HD programs.
The company reported promising 48-week clinical results for WVE-531 in DMD, showing statistically significant improvements in muscle health and function.
WVE-007 for obesity has shown potential for sustainable weight loss without muscle loss, differentiating it from current GLP-1 treatments.
WVE-006 for AATD demonstrated RNA editing in humans, with promising durability and safety profiles.
The company has a strong cash position, with $243.1 million in cash and equivalents, expected to fund operations into 2027.

Negative

WAVE Life Sciences Ltd (WVE) reported a decrease in revenue for Q1 2025 compared to the previous year, primarily due to timing of revenue recognition under a collaboration agreement.
Research and development expenses increased significantly, contributing to a higher net loss of $46.9 million for the quarter.
The company faces risks and uncertainties related to forward-looking statements and regulatory approvals, particularly for accelerated approval pathways.
There is potential competition and differentiation challenges in the RNA editing space, particularly with DNA editing technologies.
The company has not yet disclosed specific time points for data cutoffs in its clinical trials, which may impact investor confidence.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

WVE.OQ - WAVE Life Sciences Ltd
Q1 2025 WAVE Life Sciences Ltd Earnings Call
May 08, 2025 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and welcome to the Wave Life Sciences first quarter 2025 earnings conference call.

At this time all participants are the listen-only mode. As a reminder, this call is being recorded and webcasted.

After this presentation, there'll be an opportunity to ask questions to ask questions, you may press star and one on your touchstone telephone.

To withdraw your question we press star and 2.

I now turn the call over to Kate Rosh, Vice President Investor relations and corporate affairs. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
---------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.